Gilead Sciences, Inc. has announced that it will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics Inc., a privately held company developing first-in-class cancer immunotherapies. Gilead will also receive an exclusive option to acquire the remainder of Tizona for up to an additional $1.25 billion, including an option exercise fee and potential future milestone payments.
Latham & Watkins LLP represents Tizona in the transaction with a corporate deal team led by Bay Area partner Mark Bekheit, with Orange County associate Brett Urig and Bay Area associates Michelle Lu, Raul Gonzalez and Christopher Lim; on general corporate matters by Bay Area partners Judith Hasko and Ben Potter; on intellectual property matters by Bay Area associates Jekkie Kim and Peggy Ni; on benefits and compensation matters by Bay Area partner Ashley Wagner, with Bay Area associate James Robinson; on regulatory matters by Washington, D.C. partner Ben Haas, with associate Nathan Beaton; on healthcare and privacy matters by Bay Area counsel Betty Pang and Heather Deixler; on tax matters by Bay Area partner Kirt Switzer, with New York associate Lauren Bewley; and on antitrust matters by Washington, DC partner Mandy Reeves and counsel Patrick English.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
